Symbols / TRVI Stock $13.87 +0.80% Trevi Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
TRVI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index —
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NGM · United States
Market Cap 1.95B
Enterprise Value —
Income —
Sales —
FCF (ttm) -27.86M
Book/sh —
Cash/sh —
Employees —
Insider 10d —
IPO —
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E —
PEG —
P/S —
P/B —
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio —
Current Ratio —
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.32
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA —
ROE —
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin —
Shs Outstand 141.93M
Shs Float —
Insider Own —
Instit Own —
Short Float —
Short Ratio —
Short Interest —
52W High —
vs 52W High —
52W Low —
vs 52W Low —
Beta —
Impl. Vol. —
Rel Volume —
Avg Volume —
Volume —
Target (mean) $21.91
Tgt Median $24.00
Tgt Low $16.00
Tgt High $27.00
# Analysts —
Recom —
Prev Close $13.76
Price $13.87
Change 0.80%
About

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.91
Mean price target
2. Current target
$13.87
Latest analyst target
3. DCF / Fair value
$-3.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.87
Low
$16.00
High
$27.00
Mean
$21.91

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-17 main D. Boral Capital Buy → Buy $19
2026-03-19 main Jones Trading Buy → Buy $24
2026-03-18 main Morgan Stanley Overweight → Overweight $18
2026-03-18 main D. Boral Capital Buy → Buy $19
2026-03-18 main Needham Buy → Buy $24
2026-03-09 main D. Boral Capital Buy → Buy $19
2026-03-09 reit HC Wainwright & Co. Buy → Buy $21
2026-01-09 reit HC Wainwright & Co. Buy → Buy $21
2026-01-08 main D. Boral Capital Buy → Buy $19
2025-12-19 main Stifel Buy → Buy $18
2025-11-20 main Leerink Partners Outperform → Outperform $16
2025-11-14 main D. Boral Capital Buy → Buy $19
2025-11-14 main Oppenheimer Outperform → Outperform $24
2025-11-14 main Morgan Stanley Overweight → Overweight $19
2025-11-14 main Clear Street Buy → Buy $21
2025-08-21 init Morgan Stanley — → Overweight $18
2025-08-08 main Raymond James Strong Buy → Strong Buy $27
2025-08-08 main Needham Buy → Buy $22
2025-07-01 init Cantor Fitzgerald — → Overweight $25
2025-06-02 main D. Boral Capital Buy → Buy $21
News
RSS: Latest TRVI news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
49.33
-4.26%
51.52
+51.89%
33.92
+13.43%
29.91
Research And Development
33.48
-14.98%
39.38
+66.27%
23.68
+19.41%
19.83
Selling General And Administration
15.85
+30.48%
12.15
+18.62%
10.24
+1.66%
10.07
General And Administrative Expense
15.85
+30.48%
12.15
+18.62%
10.24
+1.66%
10.07
Other Gand A
15.85
+30.48%
12.15
+18.62%
10.24
+1.66%
10.07
Total Expenses
49.33
-4.26%
51.52
+51.89%
33.92
+13.43%
29.91
Operating Income
-49.33
+4.26%
-51.52
-51.89%
-33.92
-13.43%
-29.91
Total Operating Income As Reported
-49.33
+4.26%
-51.52
-51.89%
-33.92
-13.43%
-29.91
EBITDA
-42.68
+10.69%
-47.79
-67.20%
-28.58
-2.15%
-27.98
Normalized EBITDA
-42.68
+10.69%
-47.79
-67.20%
-28.58
-2.69%
-27.84
Reconciled Depreciation
0.14
-2.04%
0.15
+19.51%
0.12
+186.05%
0.04
EBIT
-42.82
+10.67%
-47.94
-66.99%
-28.71
-2.43%
-28.02
Total Unusual Items
—
—
—
-0.15
Total Unusual Items Excluding Goodwill
—
—
—
-0.15
Net Income
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Pretax Income
-42.82
+10.68%
-47.94
-64.76%
-29.10
+0.31%
-29.19
Net Non Operating Interest Income Expense
6.54
+81.66%
3.60
-17.42%
4.36
+655.11%
0.58
Interest Expense Non Operating
0.00
-100.00%
0.00
-98.98%
0.39
-66.38%
1.16
Net Interest Income
6.54
+81.66%
3.60
-17.42%
4.36
+655.11%
0.58
Interest Expense
0.00
-100.00%
0.00
-98.98%
0.39
-66.38%
1.16
Interest Income Non Operating
6.54
+81.45%
3.60
-24.14%
4.75
+172.87%
1.74
Interest Income
6.54
+81.45%
3.60
-24.14%
4.75
+172.87%
1.74
Other Income Expense
-0.03
-106.67%
-0.01
-103.20%
0.47
+230.28%
0.14
Other Non Operating Income Expenses
-0.03
-106.67%
-0.01
-103.20%
0.47
+62.28%
0.29
Gain On Sale Of Security
—
—
—
-0.15
Tax Provision
-0.06
-113.33%
-0.03
+6.25%
-0.03
+11.11%
-0.04
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.00
Net Income Including Noncontrolling Interests
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Net Income From Continuing Operation Net Minority Interest
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Net Income From Continuing And Discontinued Operation
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Net Income Continuous Operations
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Normalized Income
-42.76
+10.75%
-47.91
-64.84%
-29.07
-0.21%
-29.01
Net Income Common Stockholders
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Diluted EPS
—
-0.47
-62.07%
-0.29
+35.56%
-0.45
Basic EPS
—
-0.47
-62.07%
-0.29
+35.56%
-0.45
Basic Average Shares
—
101.97
+2.97%
99.03
+53.44%
64.54
Diluted Average Shares
—
101.97
+2.97%
99.03
+53.44%
64.54
Diluted NI Availto Com Stockholders
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Total Other Finance Cost
—
—
—
0.38
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
193.44
+74.43%
110.90
+24.05%
89.40
-27.32%
123.02
Current Assets
191.66
+75.14%
109.43
+24.99%
87.55
-28.60%
122.62
Cash Cash Equivalents And Short Term Investments
188.26
+74.93%
107.62
+29.71%
82.97
-31.15%
120.51
Cash And Cash Equivalents
18.91
-44.53%
34.10
+5.25%
32.40
+157.34%
12.59
Other Short Term Investments
169.35
+130.32%
73.53
+45.38%
50.57
-53.14%
107.92
Receivables
—
—
—
—
Taxes Receivable
—
—
—
—
Prepaid Assets
1.26
+34.50%
0.94
-74.07%
3.62
+355.47%
0.80
Other Current Assets
2.13
+146.02%
0.87
-9.21%
0.95
-27.15%
1.31
Total Non Current Assets
1.78
+21.13%
1.47
-20.69%
1.86
+365.16%
0.40
Net PPE
0.85
-30.43%
1.23
-21.17%
1.56
+703.61%
0.19
Gross PPE
1.21
-16.68%
1.46
-13.94%
1.69
+304.06%
0.42
Accumulated Depreciation
-0.36
-57.46%
-0.23
-70.15%
-0.13
+40.44%
-0.23
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.51
+45.27%
0.35
+14.80%
0.30
+43.40%
0.21
Construction In Progress
0.00
-85.71%
0.01
-58.82%
0.02
-67.92%
0.05
Other Properties
0.68
-36.85%
1.07
-20.18%
1.34
+5495.83%
0.02
Leases
0.03
+0.00%
0.03
+0.00%
0.03
-77.69%
0.13
Other Non Current Assets
0.93
+281.89%
0.24
-18.18%
0.30
+44.88%
0.20
Total Liabilities Net Minority Interest
10.20
-9.43%
11.26
+64.18%
6.86
-55.93%
15.56
Current Liabilities
9.75
-7.23%
10.51
+80.44%
5.82
-56.54%
13.40
Payables And Accrued Expenses
6.70
-12.88%
7.69
+96.88%
3.90
-19.79%
4.87
Payables
3.91
+14.56%
3.41
+88.72%
1.81
-36.68%
2.86
Accounts Payable
3.91
+14.56%
3.41
+88.72%
1.81
-36.68%
2.86
Current Accrued Expenses
2.79
-34.81%
4.27
+103.91%
2.10
+4.23%
2.01
Pensionand Other Post Retirement Benefit Plans Current
2.75
+8.20%
2.54
+57.25%
1.61
+7.03%
1.51
Current Debt And Capital Lease Obligation
0.31
+7.72%
0.28
-6.86%
0.31
-95.64%
7.03
Current Debt
—
—
—
7.00
Other Current Borrowings
—
—
—
7.00
Current Capital Lease Obligation
0.31
+7.72%
0.28
-6.86%
0.31
+1124.00%
0.03
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
0.45
-40.29%
0.75
-27.62%
1.03
-52.13%
2.16
Long Term Debt And Capital Lease Obligation
0.45
-40.29%
0.75
-27.62%
1.03
-52.07%
2.15
Long Term Debt
—
—
—
2.15
Long Term Capital Lease Obligation
0.45
-40.29%
0.75
-27.62%
1.03
+51500.00%
0.00
Other Non Current Liabilities
—
—
—
0.00
Stockholders Equity
183.24
+83.90%
99.64
+20.71%
82.55
-23.18%
107.46
Common Stock Equity
183.24
+83.90%
99.64
+20.71%
82.55
-23.18%
107.46
Capital Stock
0.13
+36.17%
0.09
+38.24%
0.07
+13.33%
0.06
Common Stock
0.13
+36.17%
0.09
+38.24%
0.07
+13.33%
0.06
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
128.31
+37.08%
93.60
+37.08%
68.28
+13.91%
59.94
Ordinary Shares Number
128.31
+37.08%
93.60
+37.08%
68.28
+13.91%
59.94
Additional Paid In Capital
512.77
+32.66%
386.53
+20.18%
321.64
+1.28%
317.59
Retained Earnings
-329.80
-14.90%
-287.05
-20.04%
-239.13
-13.84%
-210.07
Gains Losses Not Affecting Retained Earnings
0.15
+142.62%
0.06
+310.34%
-0.03
+76.23%
-0.12
Other Equity Adjustments
0.15
+142.62%
0.06
+310.34%
-0.03
+76.23%
-0.12
Total Equity Gross Minority Interest
183.24
+83.90%
99.64
+20.71%
82.55
-23.18%
107.46
Total Capitalization
183.24
+83.90%
99.64
+20.71%
82.55
-24.69%
109.61
Working Capital
181.91
+83.89%
98.92
+21.04%
81.72
-25.17%
109.22
Invested Capital
183.24
+83.90%
99.64
+20.71%
82.55
-29.21%
116.61
Total Debt
0.75
-27.03%
1.03
-22.87%
1.34
-85.42%
9.18
Capital Lease Obligations
0.75
-27.03%
1.03
-22.87%
1.34
+4855.56%
0.03
Net Tangible Assets
183.24
+83.90%
99.64
+20.71%
82.55
-23.18%
107.46
Tangible Book Value
183.24
+83.90%
99.64
+20.71%
82.55
-23.18%
107.46
Derivative Product Liabilities
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-42.09
-10.02%
-38.26
-20.64%
-31.71
-12.55%
-28.18
Cash Flow From Continuing Operating Activities
-42.09
-10.02%
-38.26
-20.64%
-31.71
-12.55%
-28.18
Net Income From Continuing Operations
-42.76
+10.75%
-47.91
-64.84%
-29.07
+0.30%
-29.15
Depreciation Amortization Depletion
0.14
-2.04%
0.15
+19.51%
0.12
+186.05%
0.04
Depreciation
—
—
—
0.04
Depreciation And Amortization
0.14
-2.04%
0.15
+19.51%
0.12
+186.05%
0.04
Other Non Cash Items
0.46
+0.65%
0.46
-51.43%
0.95
+82.12%
0.52
Stock Based Compensation
5.18
+44.51%
3.59
+59.68%
2.25
-3.44%
2.33
Asset Impairment Charge
—
0.00
-100.00%
0.39
0.00
Operating Gains Losses
0.01
—
0.01
-93.20%
0.15
Gain Loss On Investment Securities
—
—
—
0.15
Gain Loss On Sale Of PPE
0.01
0.00
-100.00%
0.01
0.00
Change In Working Capital
-3.49
-151.14%
6.83
+277.46%
-3.85
-212.51%
-1.23
Change In Prepaid Assets
-1.48
-155.58%
2.66
+193.30%
-2.85
-374.21%
-0.60
Change In Payables And Accrued Expense
-2.01
-148.30%
4.17
+518.05%
-1.00
-58.25%
-0.63
Change In Accrued Expense
-1.42
-155.21%
2.56
+4828.85%
0.05
+108.14%
-0.64
Change In Payable
-0.60
-137.26%
1.60
+253.00%
-1.05
-11755.56%
0.01
Change In Account Payable
-0.60
-137.26%
1.60
+253.00%
-1.05
-11755.56%
0.01
Investing Cash Flow
-94.11
-337.14%
-21.53
-136.23%
59.43
+155.35%
-107.37
Cash Flow From Continuing Investing Activities
-94.11
-337.14%
-21.53
-136.23%
59.43
+155.35%
-107.37
Net PPE Purchase And Sale
-0.01
+65.71%
-0.04
+74.45%
-0.14
+13.84%
-0.16
Purchase Of PPE
-0.01
+65.71%
-0.04
+74.45%
-0.14
+13.84%
-0.16
Capital Expenditure
-0.01
+65.71%
-0.04
+74.45%
-0.14
+13.84%
-0.16
Net Investment Purchase And Sale
-94.09
-337.79%
-21.49
-136.08%
59.56
+155.56%
-107.21
Purchase Of Investment
-170.66
-73.33%
-98.46
-891.37%
-9.93
+92.13%
-126.22
Sale Of Investment
76.57
-0.52%
76.97
+10.75%
69.50
+265.75%
19.00
Financing Cash Flow
121.01
+96.82%
61.48
+877.29%
-7.91
-107.11%
111.31
Cash Flow From Continuing Financing Activities
121.01
+96.82%
61.48
+877.29%
-7.91
-107.11%
111.31
Net Issuance Payments Of Debt
-0.01
+91.27%
-0.13
+98.67%
-9.50
-62.94%
-5.83
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-0.01
+91.27%
-0.13
+98.67%
-9.50
-62.94%
-5.83
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-0.01
+91.27%
-0.13
+98.67%
-9.50
-62.94%
-5.83
Net Long Term Debt Issuance
-0.01
+91.27%
-0.13
+98.67%
-9.50
-62.94%
-5.83
Short Term Debt Payments
—
0.00
+100.00%
-9.41
—
Net Short Term Debt Issuance
—
0.00
+100.00%
-9.41
—
Net Common Stock Issuance
108.15
+76.88%
61.15
+3475.79%
1.71
-98.38%
105.41
Proceeds From Stock Option Exercised
12.95
+2691.81%
0.46
+226.76%
0.14
-98.81%
11.98
Net Other Financing Charges
-0.08
—
-0.26
-4.45%
-0.25
Changes In Cash
-15.18
-993.12%
1.70
-91.42%
19.81
+181.71%
-24.24
Beginning Cash Position
34.10
+5.25%
32.40
+157.34%
12.59
-65.82%
36.83
End Cash Position
18.91
-44.53%
34.10
+5.25%
32.40
+157.34%
12.59
Free Cash Flow
-42.10
-9.95%
-38.29
-20.23%
-31.85
-12.40%
-28.33
Interest Paid Supplemental Data
0.00
-100.00%
0.00
-98.79%
0.33
-44.28%
0.59
Amortization Of Securities
-1.64
-19.82%
-1.37
+35.67%
-2.12
-156.33%
-0.83
Common Stock Issuance
108.15
+76.88%
61.15
+3475.79%
1.71
-98.38%
105.41
Issuance Of Capital Stock
108.15
+76.88%
61.15
+3475.79%
1.71
-98.38%
105.41
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category